Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus [Phase 3]

View source ↗

Summary

This clinical trial update reports on a Phase 3 study evaluating the safety and tolerability of Dapirolizumab Pegol in participants with Systemic Lupus Erythema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Dapirolizumab Pegol (dapirolizumab pegol)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: ENROLLING_BY_INVITATION